The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
Researchers uncovered genetic loci that may influence why childhood cancer survivors of African ancestry are more likely to develop therapy-linked cardiomyopathy.
The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.
